The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| OCUL | +48.83% | -42.3% | -10.42% | -3% |
| S&P | +15.66% | +86.6% | +13.29% | +249% |
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $14.54M | -5.7% |
| Gross Profit | $12.77M | -7.9% |
| Gross Margin | 87.80% | -2.1% |
| Market Cap | $2.03B | 49.9% |
| Market Cap / Employee | $7.42M | 0.0% |
| Employees | 274 | 2.6% |
| Net Income | -$69,418.00K | -90.2% |
| EBITDA | -$67,626.00K | -50.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $344.77M | -19.3% |
| Accounts Receivable | $30.77M | 1.8% |
| Inventory | 3.5 | 45.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $74.25M | 1.1% |
| Short Term Debt | $2.76M | 60.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -55.41% | -2.0% |
| Return On Invested Capital | -59.60% | 21.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$56,718.00K | -54.8% |
| Operating Free Cash Flow | -$50,725.00K | -38.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.80 | 3.67 | 5.56 | 6.61 | 84.34% |
| Price to Sales | 22.52 | 20.82 | 28.27 | 38.54 | 63.00% |
| Price to Tangible Book Value | 3.80 | 3.67 | 5.56 | 6.61 | 84.34% |
| Enterprise Value to EBITDA | -22.54 | -15.38 | -19.33 | -27.83 | 13.89% |
| Return on Equity | -95.2% | -57.2% | -63.4% | -81.8% | -15.55% |
| Total Debt | $75.78M | $76.22M | $76.94M | $77.01M | 2.51% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
